Recursion Pharmaceuticals Inc (RXRX)
9.51
-0.27
(-2.76%)
USD |
NASDAQ |
May 21, 16:00
9.50
-0.01
(-0.11%)
After-Hours: 06:18
Recursion Pharmaceuticals Debt to Equity Ratio: 0.0028 for March 31, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.0028 |
| December 31, 2023 | 0.0025 |
| September 30, 2023 | 0.0042 |
| June 30, 2023 | 0.0039 |
| March 31, 2023 | 0.0043 |
| December 31, 2022 | 0.0013 |
| September 30, 2022 | 0.0017 |
| Date | Value |
|---|---|
| June 30, 2022 | 0.0016 |
| March 31, 2022 | 0.0014 |
| December 31, 2021 | 0.0013 |
| September 30, 2021 | 0.0012 |
| June 30, 2021 | 0.0195 |
| March 31, 2021 | -0.0536 |
| December 31, 2020 | -0.0605 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-0.0605
Minimum
Dec 2020
0.0195
Maximum
Jun 2021
-0.0049
Average
0.0016
Median
Debt to Equity Ratio Benchmarks
| Eli Lilly and Co | 2.046 |
| Absci Corp | 0.0293 |
| Palatin Technologies Inc | -- |
| Oragenics Inc | -- |
| Actinium Pharmaceuticals Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 557.85M |
| Total Liabilities (Quarterly) | 156.70M |
| Shareholders Equity (Quarterly) | 401.15M |
| Current Ratio | 4.648 |
| Net Debt Paydown Yield | -0.00% |